Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05792462
PHASE1

Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders

Sponsor: Tianjin Medical University General Hospital

View on ClinicalTrials.gov

Summary

Neuromyelitis Optica Spectrum Disorders (NMOSD) is associated with a pathological humoral immune response against the aquaporin-4(AQP-4) water channel. Baricitinib is an oral Janus kinase (JAK)1/JAK2 inhibitor that blocks the upregulated JAK-STAT pathway in patients with neuroimmune disorders, which is important in bone marrow regulation of B cell proliferation and differentiation. Baricitinib may benefit some patients with NMOSD due to the important role of B cells in the pathogenesis of NMOSD. Clinical trials may be needed to observe its efficacy and safety.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

11

Start Date

2023-04-15

Completion Date

2027-03-01

Last Updated

2026-08-11

Healthy Volunteers

No

Interventions

DRUG

Baricitinib

Baricitinib will be taken orally with a dose of 4mg once daily until the disease relapses or week 96.

Locations (1)

Tianjin Medical University General Hospital

Tianjin, Tianjin Municipality, China